申请人:KaNDy Therapeutics Limited
公开号:US10774091B2
公开(公告)日:2020-09-15
The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
本发明一般涉及含有 2-[3,5-双(三氟甲基)苯基]-N-4-(4-氟-2-甲基苯基)-6-[(7S,9aS)-7-(羟甲基)六氢吡嗪并[2,1-c][1,4]恶嗪-8(1H)-基]-3-吡啶基}-N,2-二甲基丙酰胺的新型药物制剂、其制备方法及其在医疗中的用途。